Cited by 833CAR-T cell therapy researchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Open access

Rafiq, Sarwish, Yeku, Oladapo O, Jackson, Hollie J, Purdon, Terence J, van Leeuwen, Dayenne G, Drakes, Dylan J, Song, Mei, Miele, Matthew M, Li, Zhuoning, Wang, Pei, Yan, Su, Xiang, Jingyi, Ma, Xiaojing, Seshan, Venkatraman E, Hendrickson, Ronald C, Liu, Cheng, Brentjens, Renier J·2018·Nature Biotechnology

DOI 10.1038/nbt.4195PMC PMC6126939

Open this paper in CoChat — free account

Abstract

The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding tumors can be enhanced by administering the cells in combination with immune checkpoint blockade inhibitors. Alternatively, the CAR construct has been engineered to coexpress factors that boost CAR-T cell function in the tumor microenvironment. We modified CAR-T cells to secrete PD-1-blocking single-chain variable fragments (scFv). These scFv-secreting CAR-T cells acted in both a paracrine and autocrine manner to improve the anti-tumor activity of CAR-T cells and bystander tumor-specific T cells in clinically relevant syngeneic and xenogeneic mouse models of PD-L1+ hematologic and solid tumors. The efficacy was similar to or better than that achieved by combination therapy with CAR-T cells and a checkpoint inhibitor. This approach may improve safety, as the secreted scFvs remained localized to the tumor, protecting CAR-T cells from PD-1 inhibition, which could potentially avoid toxicities associated with systemic checkpoint inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.4195

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
In-gel digestion for mass spectrometric characterization of proteins and proteomes
Shevchenko, A., Tomas, H., Havli, J., Olsen, J. V., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.468 · Cited by 4,947
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citation
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

Show all 46 references

Sorted by citations

Items 601–700 of 831

Solid tumours: Building bridges to CAR‐T success
Maher, J. F. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.179 · Cited by 5
Host Interactions with Engineered T-cell Micropharmacies
Bourne, C. M., Wallisch, P., Dacek, M. M., Gardner, T. J., Pierre, S. A., Vogt, K. C., Corless, B. C., Bah, M. A., Romero-Pichardo, J. E., Charles, A. M., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0879 · Cited by 5
PD-1 Impairs CD8+ T Cell Granzyme B Production in Aged Mice during Acute Viral Respiratory Infection
Parks, O. B., Antos, D., Eddens, T. J., Walters, S., Johnson, M., Oury, T. D., Gottschalk, R. A., Erickson, J. J., & Williams, J. V. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300094 · Cited by 5
Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia
Pan, J. (2023) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2023-028 · Cited by 5
Hydrogen Sulfide Exerted a Pro-Angiogenic Role by Promoting the Phosphorylation of VEGFR2 at Tyr797 and Ser799 Sites in Hypoxia–Reoxygenation Injury
Zhang, S., Cheng, Y., Guan, Y., Wen, J., & Chen, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084340 · Cited by 5
Dynamic Diselenide Hydrogels for Controlled Tumor Organoid Culture and Dendritic Cell Vaccination
Han, Y., Liu, C., Yin, S., Cui, J., Sun, Y., Xue, B., Jiang, C., Gu, X., Qin, M., Wang, W., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c18728 · Cited by 5
Self-citation
APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells
Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021) · Aging · doi:10.18632/aging.202578 · Cited by 5
Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy
Chaudhry, K., Dowlati, E. P., & Bollard, C. M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1911648 · Cited by 5
Protein engineering: a driving force toward synthetic immunology
Cox, J. R., & Blazeck, J. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.09.005 · Cited by 5
CAR T cell therapy for multiple myeloma: What have we learned?
Susanibar-Adaniya, S. P., Stadtmauer, E. A., & Cohen, A. D. (2022) · Leukemia · doi:10.1038/s41375-022-01539-8 · Cited by 5
Cell-based immunotherapy in gynecologic malignancies
Schaar, B. T., Krishnan, V., Tallapragada, S., Chanana, A. M., & Dorigo, O. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000518 · Cited by 5
Exercise “CALM” and make CAR-T therapy work better
Mei, H., Hari, P., & Hu, Y. (2022) · 中国科学通报：英文版 · doi:10.1016/j.scib.2022.09.009 · Cited by 5
Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe
Castiello, L., Santodonato, L., Napolitano, M., Carlei, D., Montefiore, E., Monque, D. M., D’Agostino, G., & Aricò, E. (2022) · Cancers · doi:10.3390/cancers14215351 · Cited by 5
Novel approaches to promote CAR T-cell function in solid tumors
Hull, C., & Maher, J. F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614164 · Cited by 5
Electro-activated nanozyme for in situ tumor vaccination: Synergistic multi-enzyme catalysis and electrodynamic therapy
Dai, B., Yu, H., Zhang, T., Wang, K., Xiong, W., Gong, Z., & Kai, T. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102344 · Cited by 4
Genome Engineering for Next-Generation Cellular Immunotherapies
Park, J. J.-Y., Lee, K. A. V., Lam, S. Z., Tang, K., & Chen, S. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00340 · Cited by 4
Precise CAR-T cell therapy targeting non-cancerous diseases: Advances in precision medicine and bioengineering
Zhu, C., Wang, F., Cheng, Z., Zhang, L. L., & Li, H. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100024 · Cited by 5
Advanced biomaterials for the targeted delivery of immune checkpoint inhibitors to solid tumors
Henrich, E. M., & McHugh, K. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113951 · Cited by 4
CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies
Huang, M., Wang, S., Huang, H., Li, L., & Wang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705354 · Cited by 5
Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review
Han, Q., Zhang, X., chen, L., & Zhang, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07582-0 · Cited by 4
Next generation CAR-T cells to tackle solid tumors
Abreu, T. R., Godinho‐Santos, A., Amaral, A. T., Paiva, A. A., Moreira, J. N., & Gonçalves, J. R. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114650 · Cited by 5
Expression, purification and characterisation of a human anti-CDK4 single-chain variable fragment antibody
Zhao, J., Xu, J., Yang, T., Yu, X., Cheng, C., Zhang, T., Ren, Z., Li, N., Yang, F., & Li, G. (2021) · BMC Biotechnology · doi:10.1186/s12896-021-00729-z · Cited by 4
Augmenting CAR T-cell Functions with LIGHT
Cai, W., Tanaka, K., Mi, X., Rajasekhar, V. K., Khan, J. F., Yoo, S., de Stanchina, E., Rahman, J. A., Mathew, S., Abrahimi, P., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0246 · Cited by 4
Self-citation
Simultaneous Induction of Immunogenic Pyroptosis and PD-L1 Downregulation by One Single Photosensitizer for Synergistic Cancer Photoimmunotherapy
Chen, W., Qiu, J., Li, P., Zhang, Q., Li, D., Li, G., & Shan, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02747 · Cited by 4
Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review
Zheng, W., Xue, Q., Sha, X., Wang, Y., Wang, Y., Liu, J., Zhang, Y., & Shi, W. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1967083 · Cited by 4
Développement des CAR-T allogéniques
Alcazer, V., & Depil, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.01.025 · Cited by 5
Secretory co-factors in next-generation cellular therapies for cancer
Okuma, A., Ishida, Y., Kawara, T., Hisada, S., & Araki, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907022 · Cited by 5
Adenovirus vector-mediated single chain variable fragments target the nucleocapsid protein of porcine epidemic diarrhea virus and protect against viral infection in piglets
Wang, F., Zhang, Q., Zhang, F., Zhang, E., Li, M., Shiwei, M., Guo, J., Yang, Z., & Zhu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1058327 · Cited by 4
Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering
Zhang, M. H., Slaby, E. M., Stephanie, G., Yu, C., Watts, D. M., Liu, H., & Szeto, G. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00560 · Cited by 4
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors
Esmaeilzadeh, A., Jafari, D., Elahi, R., Bazargan, M., Rafie, M. Z., & Mansourabadi, A. H. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_156 · Cited by 4
Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphomaPreprint
Zhang, J., Hu, Y., Yang, J., Li, W., Tian, Y., Wei, G., Zhang, L., Zhao, K., Qi, Y., Tan, B., et al. (2020) · medRxiv · doi:10.1101/2020.09.22.20199786 · Cited by 4
CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges
Golmohammadi, M., Noorbakhsh, N., & Kavianpour, M. (2025) · Advanced Biomedical Research · doi:10.4103/abr.abr_531_23 · Cited by 3
BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer
Chiello, J. L., Shaikh, N., Jacobi, J. J., Gaulin, N., Santos, G. S., Keck, C., Hess, S. M., Lichty, B. D., Singh, P. K., Rosario, S. R., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.047 · Cited by 4
Nanomedicine-mediated co-expression of a PD-1 blockade agent and CXCL9 synergizes T cell infiltration and activation in solid tumors
Wang, Y., Zhao, L., Luo, J.-Y., Li, J., Gao, X., Li, H.-X., Zheng, Y., & Liu, J. (2025) · Biomaterials Science · doi:10.1039/d5bm01105a · Cited by 3
Engineering the tumor microenvironment: oncolytic NDV to facilitate CAR-T cell therapy
Wang, M., Jiang, K., Aicher, A., & Heeschen, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07342-0 · Cited by 3
CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions
Zhao, R., Xia, J., Zheng, Y., Huang, W., Yu, L., & Wang, L. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201099 · Cited by 3
NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions
Liu, C., Wang, Z., Zhang, W., Cheng, G., Cheng, S., Qin, L., Ye, H., & Ren, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1763843 · Cited by 3
Self-citation
Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions
Lan, F., Song, J., Chen, X., & (9093), Y. Z. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.02.011 · Cited by 3
Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting
Sharma, S. R. K., Saha, S., Arora, S., Ahlawa, Y. K., Sheoran, S., Mukherjee, S., Sinha, A., Chaudhary, K., & Gosipatala, S. B. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100012 · Cited by 3
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models
Abrahimi, P., Khan, J. F., Duren-Lubanski, A., Cai, W., Marouf, Y., Chen, N., Hirschhorn, D., Mammone, R. M., Miranda, I. C., Tallman, J. E., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20250699 · Cited by 3
Self-citation
Biology of CAR-T Cells
Berger, T. R., Boardman, A., Brentjens, R. J., & Maus, M. V. (2021) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_3 · Cited by 3
Self-citation
CAR-T Cells: A Breakthrough in Cancer Treatment
Sriwastava, A., Gupta, S., Kumar, A., Gupta, S., & Kumar, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005110 · Cited by 3
Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis
Lv, K., Du, X., Chen, C., & Yu, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1361530 · Cited by 3
Construction and characterization of a novel secreted MsC-CAR-T cell in solid tumors
Mao, Y., Chen, Y., Yang, X., He, Y., Cui, D., Huang, W. M., Jiang, L., Zhou, X., Chang, X., Zhu, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217382 · Cited by 3
CV1-secreting sCAR-T cells potentiate the abscopal effect of microwave ablation in heterogeneous tumors
Cao, B., Liu, M., Xiao, Z., Leng, D., Zhou, Y., Zhang, Z., Wang, L., Huang, X., Ni, Q., Cheng, W., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101965 · Cited by 3
Endosialin-directed CAR-T cell therapy: A promising approach for targeting triple-negative breast cancer
Wali, A. F., Talath, S., Sridhar, S. B., El‐Tanani, M., & Rangraze, I. R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167852 · Cited by 3
Genetically modified immune cells for cancer immunotherapy
Jiang, L., & Wang, W. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9395-0 · Cited by 3
Cell-based immunotherapy in gynecologic malignancies
Kamat, K. D., Krishnan, V., Berek, J. S., & Dorigo, O. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000676 · Cited by 3
Overcome tumor relapse in CAR T cell therapy
Huo, C., Yang, J., Gu, Y., Wang, D.-J., Zhang, X., & Li, Y. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02847-2 · Cited by 3
The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells
Gao, S., & Sugimura, R. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_10 · Cited by 3
Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective
Jin, G., Chang, Y., Harris, J. D., & Bao, X. (2023) · Cells Tissues Organs · doi:10.1159/000528838 · Cited by 4
Novel technologies for applying immune checkpoint blockers
Awad, R. M., & Breckpot, K. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.003 · Cited by 3
Near-Infrared Molecular Logic Gate for In Situ Construction and Quantification of Cell–Macromolecule Conjugates
Tang, Y., Liu, S., Hao, X., Wang, Z., Liang, M., Lü, Y., & Zhou, X. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03486 · Cited by 3
Mitochondrial transporter expression patterns distinguish tumor from normal tissue and identify cancer subtypes with different survival and metabolism
Wohlrab, H., Signoretti, S., Rameh, L. E., DeConti, D. K., & Hansen, S. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-21411-0 · Cited by 4
Killing Efficiency Affected by Mutually Modulated PD-1 and PD-L1 Expression via NKT-hepatoma Cell Interactions
Liu, L., Yang, M., Qia, X., Zhou, M., Cheng, Y., Xu, H., Qin, Y., & Liu, B. (2020) · Immunotherapy · doi:10.2217/imt-2020-0062 · Cited by 3
Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”
Golubovskaya, V. (2023) · Cancers · doi:10.3390/cancers15205053 · Cited by 3
PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models
Chen, W., Xian, N., Zhao, N., Zhang, Q., & Xu, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310430 · Cited by 2
Role of YY1 in pancreatic ductal adenocarcinoma: Mechanisms and therapeutic perspectives
Pellakuru, P., Guenter, R. E., Hariharan, N., & Nagaraju, G. P. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189415 · Cited by 2
Emerging innovative treatments for leptomeningeal metastatic tumors
Kanaya, N., & Shah, K. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.10.008 · Cited by 2
Optimization of CAR-T technology to improve the effectiveness of therapy for solid tumors
Bozhenko, K. V., Kiseleva, Y. Y., Bayramov, A. V., Шишкин, А. М., Гуламовна, А. К., Михайловна, К. Т., Александровна, К. Е., & Solodkiy, V. А. (2025) · Immunologiya · doi:10.33029/1816-2134-2025-46-5-640-650 · Cited by 2
Targeting strategies and immune regulatory mechanisms of CAR-macrophages in the treatment of osteosarcoma
Rongrong, C. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102602 · Cited by 2
Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer
Wutti‐in, Y., Luangwattananun, P., Sawasdee, N., Vongchan, P., Yenchitsomanus, P., & Panya, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118967 · Cited by 2
Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions
Han, S. Z., Yue, J., Zheng, H., Huang, Y., Kong, D., Wei, G., Hu, Y., & Huang, H. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3061-8 · Cited by 2
Coated oncolytic viruses based “double strike” strategy triggering CD19 CAR-T therapy in gastrointestinal tumors
Zhang, H., Wen, K., Liu, T., Zhang, Y., Yang, X., Zhang, H., Wang, H., Zuo, S., Zheng, J., Geng, H., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124143 · Cited by 2
CRISPR-Cas9 engineering of CAR-T cells: Can non-viral nanoparticles unlock safer and scalable genome editing?
My, B., Lia, A., Rizzo, L., Maiorano, G., Galeone, A., Palamà, I. E., & Gigli, G. (2026) · iScience · doi:10.1016/j.isci.2026.115422 · Cited by 2
Application of CAR-T therapy in solid tumors: current opportunities and challenges
Wang, A., Ye, X., Zhao, Y., Huang, D., & Zhang, C. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01033-8 · Cited by 2
CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to Efficacy
Liu, K., Pham, V. T., Fu, S., Sun, L., & Huang, G. (2026) · Hematological Oncology · doi:10.1002/hon.70209 · Cited by 2
Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review
Li, D., Lu, J., Li, Q., Deng, H., & Tan, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060752 · Cited by 2
Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma
Perica, K., Palomba, M. L., & Brentjens, R. J. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.23 · Cited by 2
Self-citation
EASINESS: E. coli Assisted Speedy affINity-maturation Evolution SyStem
Zhang, H., Xue, J., Wang, A. Z.-L., Jiang, H., Merugu, S. B., Li, D., & Tao, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747267 · Cited by 2
Deep Downregulation of PD‐L1 by Caged Peptide‐Conjugated AIEgen/miR‐140 Nanoparticles for Enhanced Immunotherapy
Dai, J., Hu, J., Dong, X., Chen, B., Dong, X., Liu, R., Xia, F., & Lou, X. (2022) · Angewandte Chemie · doi:10.1002/ange.202117798 · Cited by 2
PRECLINICAL MOUSE MODELS IN ADOPTIVE CELL THERAPIES OF CANCER
Rajčević, U., & Smole, A. (2022) · Slovenian Veterinary Research · doi:10.26873/svr-1513-2022 · Cited by 2
Precision Targeting and Genetically Modified T Cells for Targeting Cancer Cells
Mahmood, A. A. R., Srinivasan, S., & Challaraj Emmanuel, E. S. (2024) · International Journal of Trends in OncoScience · doi:10.22376/ijtos.2023.2.1.1-9 · Cited by 2
Cancer Cell‐Selective PD‐L1 Inhibition via a DNA Safety Catch to Enhance Immunotherapy Specificity
Bi, S., Chen, W., Fang, Y., Shen, J., Zhang, Q. H., Guo, H., Ju, H., & Liu, Y. (2024) · Angewandte Chemie · doi:10.1002/ange.202402522 · Cited by 2
Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties
Nunoya, J.-I., Imuta, N., & Masuda, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168662 · Cited by 2
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity
Zheng, Y., Lu, Z., Zhu, F., Shao, Y., Shao, Y., Lu, B., Ding, J., Fang, L., Fang, L., Zheng, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113004 · Cited by 2
The Application Progress, Challenges, and Future Directions of Gene Editing Technology in Immunotherapy
Zou, J. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/1x4qt075 · Cited by 2
Enhancing the antitumor activity of CD19/BCMA CAR-T cells in vitro with a PD1IL7R chimeric switch receptor
Yan, K., & Xiao, Z. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.105001 · Cited by 2
A Bidirectional EF1 Promoter System for Armoring CD19 CAR-T Cells with Secreted Anti-PD1 Antibodies
Khaniya, A., Khuisangeam, N., Tawinwung, S., Suppipat, K., & Hirankarn, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311566 · Cited by 2
Perspectives d’évolution et d’utilisation des cellules CAR-T
Genebrier, S., & Tarte, K. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.04.021 · Cited by 2
Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers
Gao, H., Qu, L., Li, M., Guan, X., Zhang, S., Deng, X., Wang, J., & Xing, F. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139829 · Cited by 2
Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes
Mandavkar, A. A., Padakanti, S. S. N., Gupta, S., Akram, S., Jaffar, N., Chauhan, J., Allu, L. R., Saini, P., Nasrallah, J., Omar, M. A., et al. (2025) · Human Antibodies · doi:10.1177/10932607241301699 · Cited by 2
Advances in CAR-T Cell Therapy for Solid Tumors
Li, Y., Zuo, B., Xing, Y., Zhang, R., Jia, L., Yan, B., Yang, A., & Yin, H. (2025) · Immune discovery. · doi:10.70322/immune.2025.10006 · Cited by 2
CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through
Zhang, Q., Zu, C., Hu, Y., & Huang, H. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2080820 · Cited by 2
Combinatorial Strategies for T Lymphocyte-Based Cancer Immunotherapy
Hargadon, K. M., & Wall, J. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_211-1 · Cited by 2
Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
Baidoun, F., Merjaneh, Z., Abd‐Elhay, F. A., & Kamel, M. G. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101156 · Cited by 2
Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march
Rafei, H., Başar, R., Rezvani, K., & Daher, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00021-5 · Cited by 1
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL
Wang, G., Huang, M., Jiang, L., Zhang, X., Wang, Z. M., Yu, Q., Li, D., Yang, Y., Yang, X., & Cao, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04001-7 · Cited by 1
CAR T Cell Strategies for Metastatic Breast Cancer
Shah, P. D. (2025) · Cancer immunotherapy · doi:10.1007/13905_2024_43 · Cited by 1
Study on the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109
Peng, S., Li, Y., Zhang, Y., Min, J., An, R., Du, N., Li, H., Zhen, X., Chu, F., & Li, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03747-x · Cited by 1
Self-citation
Spatiotemporal organelle delivery and activation of type I AIE photosensitizers and siRNA for near-infrared fluorescence image-guided immunotherapy
Dong, M., Wang, X., Yang, J., Peng, W., Yang, S., Xiang, Q., Zheng, J., Dong, H., & Zhang, X. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123827 · Cited by 1
mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma
Feng, Y., Du, Y., Zhang, C.-T., Xie, F., & Yan, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189493 · Cited by 2
Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients
Singh, G., Kumari, L., Katoch, D., Sood, A., Thakur, N., Singh, K., & Kumar, U. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103562 · Cited by 2
Combinatorial Strategies for T Lymphocyte-Based Cancer Immunotherapy
Hargadon, K. M., & Wall, J. B. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_211 · Cited by 1
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
Litvin, R. F. D. A., & Hill, B. T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2621889 · Cited by 1
Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies
Ogusuku, I. E. Y., Knelangen, N., Engels, B., Subklewe, M. S., & Lock, D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.006 · Cited by 1
Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells
Nianias, A., Katsarou, A., Prins, H. J., Shahrabi, A., van Velzen, C., Henneman, L., Ruiter, R. W. J., Mutis, T., Groen, R. W. J., & Themeli, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757174 · Cited by 1
MUC1-targeted CAR-T cell secreted anti-PD-1 IgG antibody enhances antitumor activity in Cholangiocarcinoma
Khuisangeam, N., Chinsuwan, T., Intanachai, T., Thaiwong, R., Boonkrai, C., Phakham, T., Pisitkun, T., Suppipat, K., Hirankarn, N., & Tawinwung, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-49988-w · Cited by 1
Reinvigorating the Cancer‐Immunity Cycle With Combined Oncolytic Virus and CAR‐T Cell Therapies in Solid Tumors
Watanabe, K., & Nishikawa, H. (2026) · Pathology International · doi:10.1111/pin.70117 · Cited by 1
Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer
Chen, X., Huang, J., Diao, G., Tian, M., Yang, Y. S., Liu, D. Y., Ma, Y., Han, J., & Guo, J. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04443-7 · Cited by 1

Authors: Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., Yan, S., Xiang, J., Ma, X., Seshan, V. E., Hendrickson, R. C., Liu, C., & Brentjens, R. J.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Cornell University (US)
Weill Cornell Medicine (US)
Eureka Therapeutics (United States) (US)
Corresponding author: Brentjens, Renier J
ORCID: Rafiq, Sarwish
Yeku, Oladapo O
Purdon, Terence J
van Leeuwen, Dayenne G
Drakes, Dylan J
Song, Mei
Miele, Matthew M
Li, Zhuoning
Yan, Su
Xiang, Jingyi
Ma, Xiaojing
Seshan, Venkatraman E
Hendrickson, Ronald C
Brentjens, Renier J
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2018-08-13
Volume: 36
Issue: 9
Pages: 847-856
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4195
PMC: PMC6126939
OpenAlex: W2886131798
Cited by: 833
References: 46
Citations by year: 2026: 78 · 2025: 94 · 2024: 91 · 2023: 114 · 2022: 123 · 2021: 121 · 2020: 122 · 2019: 72 · 2018: 14
FWCI: 31.01
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (1s10od010598-01)
National Cancer Institute (P01CA190174, P50CA192937, P30CA008748)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: chimeric antigen receptor T cells, anti-PD-1 therapy, scFv, chimeric antigen receptor, immune checkpoint blockade, PD-L1, paracrine signaling, autocrine signaling, bystander T cells, tumor microenvironment, hematologic malignancies, solid tumors, CAR T cell safety
MeSH terms: Receptors, Chimeric Antigen, Animals, Humans, T-Lymphocytes, Xenograft Model Antitumor Assays, Mice, Single-Chain Antibodies, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks